1. Home
  2. HNRG vs DRTS Comparison

HNRG vs DRTS Comparison

Compare HNRG & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HNRG

Hallador Energy Company

HOLD

Current Price

$18.96

Market Cap

790.0M

Sector

Energy

ML Signal

HOLD

Logo Alpha Tau Medical Ltd.

DRTS

Alpha Tau Medical Ltd.

HOLD

Current Price

$8.41

Market Cap

641.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HNRG
DRTS
Founded
1949
2015
Country
United States
Israel
Employees
N/A
121
Industry
Coal Mining
Medical/Dental Instruments
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
790.0M
641.6M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
HNRG
DRTS
Price
$18.96
$8.41
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
3
Target Price
$25.38
$8.67
AVG Volume (30 Days)
1.0M
421.8K
Earning Date
05-06-2026
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
116.78
N/A
EPS
N/A
N/A
Revenue
$469,466,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$12.12
$699.98
P/E Ratio
N/A
N/A
Revenue Growth
16.09
N/A
52 Week Low
$14.68
$2.81
52 Week High
$24.70
$9.07

Technical Indicators

Market Signals
Indicator
HNRG
DRTS
Relative Strength Index (RSI) 67.36 59.76
Support Level $18.89 $6.47
Resistance Level $20.80 $8.60
Average True Range (ATR) 1.17 0.63
MACD 0.46 -0.00
Stochastic Oscillator 52.27 66.63

Price Performance

Historical Comparison
HNRG
DRTS

About HNRG Hallador Energy Company

Hallador Energy Co is a vertically integrated, independent power producer (IPP) and fuel company with operations in Indiana. The Company operates across multiple stages of the energy value chain, from accredited capacity and energy to coal. The Company's electric operations are located within the Midcontinent Independent System Operator's (MISO) footprint. The company's business is organized based on the services and products it provide in two segments: (i) Electric Operations and (ii) Coal Operations.

About DRTS Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.

Share on Social Networks: